Pharmabiz21h
Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML
Daiichi Sankyo begins patient dosing in QuANTUM-Wild phase 3 trial of Vanflyta in newly diagnosed FLT3-ITD negative AML: Tokyo Thursday, December 12, 2024, 12:00 Hrs [IST] The fir ...
Daiichi Sankyo doses first subject in Phase III AML therapy trial
Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
New York Post23d
Suspected madman stabber has long criminal history — and was released from NYC jail just one month before deadly spree
The suspected madman behind a deadly stabbing spree in Manhattan Monday has a long criminal history — and had just walked free from Rikers Island a month before the terrifying attacks, The Post ...